Forbes - USA (2019-12-31)

Emerging Markets 1

PROMOTIONPROMOTION

Nanopharmacia Group:

HEALTH INNOVATION FOR LATIN AMERICA

The World Health Organization proj-
ects that the number of new cases of dia-
betes and cancer in Latin America could
increase by more than 70% in the next
decade. Preventing and combatting these
diseases requires innovation and invest-
ment. The Mexican company Nanophar-
macia Group offers both.
The company is rising to the chal-
lenges of health care in Mexico and Latin
America. It is the only private company in
Latin America in the business of develop-
ing new therapeutic products using nano-
technology to treat diabetes and cancer.

“Diabetes is a metabolic disease that
has increased dramatically in Mexico in
the last 10 years, and cancer is a complex
disease closely linked to multiple factors
including metabolic and infectious,” says
Horacio Astudillo de la Vega, Nanophar-
macia lead scientist, founder and partner.
Nanopharmacia Group integrates
Nanopharmacia Diagnostica, a leader
in precision cancer medicine in Mexico;
Nanoclinic, a clinical laboratory diagnos-
tic firm; Healthcare Business and Com-
puter Technologies, which offers novel
supplement combinations and medical
device technologies; and DNI Genet-
ics & Nutrition, developer of genetic
metabolism diagnostics and personalized

nutritional treatments. Each company is

already active commercially with prod-

ucts and services, using 100 % Mexican-

owned scientific developments.

Nanopharmacia Group has evaluated

more than 4 0,000 cases in the last eight

years and serves patients with chronic

degenerative diseases at both public and

private institutions. Its private Nano-

pharmacia Foundation was established

to further provide research and support

for disease prevention and cures.

Improving Lives With Detection and

Advanced Treatments

“In Mexico, a national program for

timely detection has not been estab-

lished,” says Astudillo de la Vega. “Dia-

betes treatment and detection strate-

gies have not had a favorable impact on

disease control in our country. In Latin

America, the situation is no less serious,

as in Mexico, the high cost of medical

and pharmaceutical interventions is not

accessible to the entire population.” By

offering advanced early-detection and

diagnostic tools, Nanopharmacia hopes

to improve lives.

As it continues to innovate, the com-

pany is looking to expand the market for

its supplement products. Some of these

formulations, improved with the use of

nanotechnology, have been proven benefi-

cial for regulating the metabolic behavior

of complex diseases such as diabetes and

cancer. Some of Nanopharmacia’s supple-

ment formulations have been granted

patents in the United States, the EU

and in more than 4 0 countries including

China, India and Russia. Many more are

in the pipeline.

Nanopharmacia’s product DIAKRONE

developed by Nanopharmacia has demon-

strated benefits for patients with diabetes

and diabetic complications. DIAKRONE

was approved by Mexico’s health and drug

regulatory agency COFEPRIS to start the

first study with diabetic patients, a step

toward the product’s approval.

“The global market for advanced

molecular diagnosis and supplements is

one of the fastest growing in the world,”

says Astudillo de la Vega. “It is estimated

that it will reach more than $ 16 billion by

2025, especially for products that offer

combinations with improved efficacy

based on the use of nanotechnology as we

are doing now. This segment of develop-

ment in pharmaceutical and scientific

innovation is undoubtedly the one with

the greatest acceleration in investment

for new businesses.”

Editor in Chief Paul Trustfull

Nanopharmacia Laboratory Machine

Horacio Astudillo de la Vega, Nanopharmacia
lead scientist, founder and partner

Paul Trustfull and Horacio Astudillo de la Vega